RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)—Quintiles is benoemd tot marktleider in Fase IV-diensten voor het derde jaar op rij, volgens het 2015 CRO Quality Benchmarking – Phase IV Service Providers Report van Industry Standard Research (ISR).
Quintiles is geselecteerd als de voorkeursleverancier onder biofarmaceutische bedrijven voor Fase IV-diensten gebaseerd op een onderzoek onder 110 mondiale biofarmaceutische vertegenwoordigers. In het rapport werd Quintiles scoorde het beste op een aantal punten, waaronder de breedte van de dienstverlening, mondiale voetafdruk en technologie waardoor realtime toegang tot informatie mogelijk wordt geleverd door het prijswinnende Quintiles Infosario®-platform.
Quintiles Recognized as Phase IV Services Leader for Third Consecutive Year
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Quintiles has been named the market leader in Phase IV services for the third year in a row, according to the 2015 CRO Quality Benchmarking – Phase IV Service Providers Report from Industry Standard Research (ISR).
Quintiles was selected as the preferred provider among biopharmaceutical companies for Phase IV services based on a survey of 110 global biopharmaceutical representatives. In the report, Quintiles was highlighted as a leader across a number of key service quality metrics, including its service breadth, global footprint and technology that enables real-time data access delivered by its award-winning Quintiles Infosario® platform.
“We are proud to be honored once again for our leadership in Phase IV services across all of our customer segments,” said Andrea Spannheimer, senior vice president, Real-World & Late Phase Research at Quintiles. “This acknowledgement reflects our unmatched depth and breadth of expertise, as well as scientific affairs thought leadership and services, which are required to provide the right approach to the right question for our customers worldwide. We especially want to thank our talented employees – this recognition is a testament to their tireless dedication.”
Compared to the other 33 Phase IV Contract Research Organizations noted in the report, Quintiles was a top performer in a number of selection criteria including:
- Customer loyalty
- Performance relative to expectations
- Perceived differentiation of service quality
Survey participants were decision-makers from small, mid-size and large global biopharmaceutical companies and were required to have been involved in outsourced Phase IV trials within the past 18 months.
To learn more about the report, click here.
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Check out our twitter: @NewsNovumpr